State Street’s Bright Minds Biosciences DRUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.9M Buy
108,239
+30,961
+40% +$2.49M ﹤0.01% 2736
2025
Q4
$6.03M Buy
77,278
+8,890
+13% +$594K ﹤0.01% 2904
2025
Q3
$4.15M Buy
68,388
+43,733
+177% +$1.7M ﹤0.01% 3063
2025
Q2
$644K Buy
+24,655
New +$739K ﹤0.01% 3569

Other funds holding DRUG

State Street's DRUG Position: Q1 2026 in Review

State Street increased its Bright Minds Biosciences (DRUG) stake by 40% in Q1 2026, buying an estimated $2.49M and bringing the position to 108,239 shares worth $7.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

State Street first reported a position in DRUG in Q2 2025 and has held it in 4 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • State Street held 108,239 shares of Bright Minds Biosciences worth $7.9M as of Q1 2026.
  • State Street bought 30,961 Bright Minds Biosciences shares in Q1 2026, an estimated $2.49M.
  • Bright Minds Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2736 holding.
  • State Street first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.